OneMedNet Corporation regained Nasdaq compliance with a market value exceeding $35 million, enabling strategic growth initiatives for 2025.
Quiver AI Summary
OneMedNet Corporation announced that it has regained compliance with Nasdaq Listing Rule 5550(b)(2) after its market value exceeded $35 million for ten consecutive business days, clearing all previous deficiency notices from Nasdaq. CEO Aaron Green expressed satisfaction with this achievement, allowing the company to focus on revenue growth and operational expansion in 2025. Recent initiatives include expanding product offerings, enhancing financial reporting and business development teams, and collaborating with Bayer's AI Innovation Platform. The company also strengthened its finances by raising approximately $6.4 million through private placements and adopting a Bitcoin treasury strategy. OneMedNet's proprietary imaging Real World Data platform aims to support diverse clinical research needs and improve patient outcomes.
Potential Positives
- OneMedNet has regained compliance with Nasdaq Listing Rule 5550(b)(2), confirming its market value exceeds $35 million, which enhances its credibility and stock stability.
- The company is focusing on growth in 2025, indicating a strategic direction aimed at expanding revenue and operations.
- OneMedNet has appointed new key executives, enhancing its leadership team to drive its strategic initiatives and commercial presence in the healthcare sector.
- The company successfully raised approximately $6.4 million in private placements, improving its liquidity for future investments and growth opportunities.
Potential Negatives
- The announcement of regaining compliance with Nasdaq Listing Rule 5550(b)(2) highlights previous non-compliance issues, raising concerns about the company's past market performance and stability.
- The press release contains numerous forward-looking statements, which inherently present risks and uncertainties that could reflect a lack of concrete performance metrics or results.
- The mention of Bitcoin as part of the company’s treasury management strategy introduces concerns regarding the volatility and inherent risks associated with cryptocurrency investments.
FAQ
What recent compliance achievement did OneMedNet announce?
OneMedNet announced that it regained compliance with Nasdaq Listing Rule 5550(b)(2) after exceeding a market value of $35 million.
Who is the new Chief Financial Officer of OneMedNet?
Bob Golden has been appointed as the new Chief Financial Officer to enhance financial reporting processes.
What are OneMedNet's main product offerings?
OneMedNet's offerings include clinical imaging innovations, data masking solutions, and subscription-based healthcare data solutions.
How is OneMedNet leveraging artificial intelligence?
OneMedNet is enhancing data de-identification and curation services using Generative AI for better speed and accuracy.
What strategic partnerships has OneMedNet formed recently?
The company signed an agreement with Bayer’s AI Innovation Platform to strengthen its commercial presence in life sciences.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$ONMD Hedge Fund Activity
We have seen 11 institutional investors add shares of $ONMD stock to their portfolio, and 9 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- DISCOVERY CAPITAL MANAGEMENT, LLC / CT added 2,301,791 shares (+inf%) to their portfolio in Q3 2024
- CKW FINANCIAL GROUP removed 476,709 shares (-82.5%) from their portfolio in Q3 2024
- GEODE CAPITAL MANAGEMENT, LLC removed 83,188 shares (-44.9%) from their portfolio in Q3 2024
- CITADEL ADVISORS LLC added 49,899 shares (+inf%) to their portfolio in Q3 2024
- HRT FINANCIAL LP removed 42,620 shares (-100.0%) from their portfolio in Q3 2024
- UBS GROUP AG added 37,766 shares (+inf%) to their portfolio in Q3 2024
- BRIDGEWAY CAPITAL MANAGEMENT, LLC removed 35,827 shares (-51.8%) from their portfolio in Q3 2024
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
MINNEAPOLIS, Jan. 13, 2025 (GLOBE NEWSWIRE) -- OneMedNet Corporation (Nasdaq: ONMD) (“OneMedNet” or the “Company”), a global provider of clinical imaging innovation and curator of regulatory-grade Imaging Real World Data (“iRWD™”), inclusive of electronic health records, laboratory results and, uniquely, medical imaging, today announced that the Company regained compliance with Nasdaq Listing Rule 5550(b)(2) (the “Rule”) after the market value of the Company’s common stock exceeded $35,000,000 for 10 consecutive business days. The Company received a notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) confirming compliance with the Rule. As a result, the Company has cleared all listing deficiency notices issued by Nasdaq.
Aaron Green, Chief Executive Officer, stated, “We are pleased to have now achieved compliance with the Nasdaq listing rules. This accomplishment will enable us to focus in 2025 on growing our revenue and business operations.”
During the 2024 and 2025, we developed and started to execute on our strategic plan by:
Expanding its product offerings, which now include data masking solutions for additional industries and subscription-based offerings for the Company’s healthcare and real-world data solutions.
Appointing Bob Golden as Chief Financial Officer to oversee enhancements in the Company’s financial reporting processes.
Hiring a Director of Business Development, Margaret Nash, and Vice President of Marketing, Michael Wong, to continue to build our commercial presence with Life Science organizations, additionally recently signing an agreement with Bayer’s AI Innovation Platform (AIIP) announced in early December 2024.
Enhancing our Data De-Identification and curation service leveraging Generative AI and deploying OneMedNet’s 2.0 generation indexer OMNi, to improve the speed and accuracy of data searching and indexing.
Refreshing the composition of the Company’s Board of Directors with three new directors who have relevant industry, financial and public company expertise.
Improving liquidity by raising approximately $6.4M in private placements with Off the Chain Capital and an affiliate of Discovery Capital Management.
Enhancing treasury management with a Bitcoin on the balance sheet strategy.
OneMedNet is now in a position to take advantage of the growing Real World Data market with a meaningful market share.
About OneMedNet Corporation
OneMedNet provides innovative solutions that unlock the significant value contained within the Real-World Data (“RWD”) repositories of over 1,400 healthcare system and provider sites that currently comprise its iRWD™ network. OneMedNet’s proprietary iRWD™ platform provides secure, comprehensive management of diverse clinical data types, including electronic health records, ECGs, EEGs, prescriptions, physician notes, laboratory results, and uniquely, medical imaging. Employing its robust iRWD™ platform, the Company securely de-identifies, searches, and curates the clinical data, bringing a wealth of internal and third-party research opportunities to its drug, medical device and imaging/diagnostic AI development customers.
OneMedNet’s platform is designed to address diverse clinical requirements across various domains, such as rare diseases, central nervous system disorders, oncology, cardiology and women’s health. The Company is committed to delivering precise and robust research support services that span the entire continuum of care. This commitment is a cornerstone of OneMedNet’s strategy to enhance patient outcomes and help pave the next wave of healthcare innovation. For more information, please visit www.onemednet.com.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements. In addition, from time to time, we or our representatives may make forward-looking statements orally or in writing. We base these forward-looking statements on our expectations and projections about future events, which we derive from the information currently available to us. Such forward-looking statements relate to future events or our future performance, including: our financial performance and projections; our growth in revenue and earnings; and our business prospects and opportunities. You can identify forward-looking statements by those that are not historical in nature, particularly those that use terminology such as “may,” “should,” “expects,” “anticipates,” “contemplates,” “estimates,” “believes,” “plans,” “projected,” “predicts,” “potential,” or “hopes” or the negative of these or similar terms. In evaluating these forward-looking statements, you should consider various factors, including: our ability to change the direction of OneMedNet; our ability to keep pace with new technology and changing market needs; the competitive environment of our business; risks inherent with investing in Bitcoin, including Bitcoin’s volatility; and our ability to implement our Bitcoin treasury strategy and its effects on our business. These and other factors may cause our actual results to differ materially from any forward-looking statement. Forward-looking statements are only predictions. The forward-looking events discussed in this press release and other statements made from time to time by us or our representatives, may not occur, and actual events and results may differ materially and are subject to risks, uncertainties, and assumptions about us. We are not obligated to publicly update or revise any forward-looking statement, whether as a result of uncertainties and assumptions, the forward-looking events discussed in this press release and other statements made from time to time by us or our representatives might not occur.
OneMedNet Contacts:
Michael Wong, VP Marketing
Email:
michael.wong@onemednet.com
SOURCE: ONEMEDNET CORPORATION
This article was originally published on Quiver News, read the full story.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
